During the 4 weeks of IFN-γ monotherapy, GVHD biomarkers did not rise, suggesting that IFN-γ alone did not trigger a GVHD response, concordant with the absence of clinical GVHD before DLI. The gene discussed is IFNG; the disease is graft versus host disease.